He also holds an Associate Scientist appointment at the Ottawa Hospital Research Institute Clinical Epidemiology and Regenerative Medicine Programs. His current research is largely preclinical and translational, focusing on novel therapies (e.g. mesenchymal stem cell therapy for inflammatory diseases, CAR-T cells for hematologic malignancies). As a new investigator he has received funding to develop an evidence based approach to prepare for an early phase trial of chimeric antigen receptor T-cell therapy. Dr. Lalu has also received funding for a network meta-analysis of preclinical agents for stroke. Dr. Lalu has an interest in assessing and reducing risk of bias in preclinical work (with an eye to improving clinical translation) and has been funded to assess barriers to reducing bias in bench work.